NATCO Pharma receives USFDA EIR with VAI classification for Visakhapatnam FDF unit

By: IPP Bureau

Last updated : November 21, 2026 8:38 am



The company had received Four observations in the Form 483


NATCO Pharma Limited receives Establishment Inspection Report (EIR) from US FDA Inspection at our Visakhapatnam, Andhra Pradesh, FDF Unit

The U.S. Food and Drug Administration (FDA) had conducted an inspection at the FDF manufacturing plant located in Parawada, Visakhapatnam, Andhra Pradesh, India, which was conducted from August 17th – August 21st, 2026.

On conclusion of the inspection, the company had received Four observations in the Form 483. We hereby notify that the company has received EIR from the U.S. FDA on the classification as Voluntary Action Indicated (VAI).

NATCO Pharma Limited Establishment Inspection Report USFDA

First Published : November 21, 2026 12:00 am